cel-sci.com (CVM) Long-Term Debt to Capital Ratio

CEL-SCI Corp - graphic logo of issuer CVM

CEL-SCI Corporation operates amid investor skepticism due to prolonged development timelines. The long-term financial leverage ratio demonstrates current stability, where the value of 0.45 reflects the current level of borrowings. Prospects depend on the certification of GMP facilities and the success of Multikine, as well as the flawless transportation of experimental vaccines between centers.

Long-Term Debt to Capital: CEL-SCI Corp. (CVM) for 07/04/2022 - 10/30/2026
Flagship merchandise of CEL-SCI Corporation

This ratio determines the share of long-term liabilities within the equity structure, measuring the company's degree of financial leverage. An increase in this metric signals a rising credit burden, which requires correlation with revenue growth rates. By analyzing the dynamics of long-term debt relative to equity, an investor can discern the actual trajectory of the debt policy. For CEL-SCI Corporation (CVM), low values confirm the efficiency of production outsourcing. The absence of significant capital expenditures minimizes the need for long-term borrowing.

Competing companies

Long-Term Debt to Capital BeiGene Ltd.|Long-Term Debt to Equity Halozyme Inc. (HALO)|Revolution Medicines Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital AAPG (Ascentage Pharma Group)|CGON - Long-Term Debt to Equity Ratio|UroGen Pharma - Long-Term Debt to Capital|Long-Term Liabilities to Capital Bicara Therapeutics Inc|Personalis Corp (PSNL) - Long-Term Debt to Equity|Erasca Oncology - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio DCTH|YMAB: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital AURA|Long-Term Debt to Equity Ratio candeltx.com CADL|Accuray Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital SELLAS Life Sciences Group, Inc. SLS|ACTU - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient CTOR (citiusonc.com)|HURA: Long-Term Debt to Capital|Long-Term Liabilities to Capital Protara Therapeutics Inc (TARA)|FATE (Fate Therapeutics Corp) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Aadi Bio (WHWK)|Long-Term Debt to Capital TCRX|CSBR - Long-Term Liabilities to Capital|Long-Term Debt to Equity XBiotech XBIT|OS Therapies Inc. - Long-Term Debt to Equity|RADX: Long-Term Debt to Equity Ratio|Long-Term Indebtedness to Equity Artiva Biotherapeutics, Inc. (ARTV)|adlainortye.com (ANL) - Long-Term Debt to Equity|VERU - Ratio of Long-Term Indebtedness to Capital|TPST (Tempest Therapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Xilio (XLO)|Long-Term Debt to Capital RENB|Ratio of Long-Term Indebtedness to Capital muraloncology.com|Kairos Pharma - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient OKUR|CytoMed - Long-Term Debt to Capital|Curis, Inc. (CRIS) - Long-Term Debt to Equity Ratio|apollomicsinc.com (APLM) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Tharimmune Corporation (THAR)|Long-Term Debt to Equity Advanced Biomed Inc.|GNPX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Calidi Biotherapeutics (CLDI)|SBFM: Long-Term Liabilities to Equity|Long-Term Debt to Equity Xenetic Biosciences, Inc. XBIO|Salarius Pharma (SLRX) - Long-Term Liabilities to Capital|PPBT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient AONC (American Oncology Network)|BGNE: Long-Term Debt to Capital|Checkpoint Therapeutics Inc. (CKPT) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio ELEV|ICAD (iCAD Corp) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital IKNA|Ratio of Long-Term Indebtedness to Capital notablelabs.com|Long-Term Debt to Equity Viracta Therapeutics, Inc. VIRX|MorphoSys Inc (MOR) - Long-Term Liabilities to Capital|NAYA - Long-Term Debt to Equity|AAPGV (Ascentage) - Long-Term Debt to Capital Ratio